Mitsuo Sato
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Mitsuo Sato has a total of 199 co-authors. Here are the top co-authors by number of shared publications:
Yoshinori Hasegawa
National Hospital Organization Nagoya Medical Center, Nagoya, Japan
18 shared publicationsMasashi Kondo
Department of Respiratory Medicine, Fujita Health University, Toyoake, Japan
14 shared publications- Tetsunari Hase
Department of Respiratory Medicine Nagoya University Graduate School of Medicine Nagoya Japan
12 shared publications John D. Minna
Hamon Center for Therapeutic Oncology Research and the Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX, 75230-8593, USA
11 shared publicationsYoshitaka Sekido
Division of Cancer Biology Aichi Cancer Center Research Institute Nagoya Japan
11 shared publicationsKenya Yoshida
Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan
10 shared publications
Latest Publications
- 10 March 2026
- Published by Wiley in Respirology
Epigenetic Scarring and a Vulnerable Mucus–Barrier Axis in Ex‐Smokers With COPD
- 10 March 2026
- Published by Wiley in Respirology
Epigenetic Scarring and a Vulnerable Mucus–Barrier Axis in Ex‐Smokers With COPD
- Open Access
- 10 February 2026
- Published by Elsevier in Respiratory Investigation
- Vol. 64 (2) , 101383
Favorable clinical impact of histological subtype with non-small cell carcinoma-not otherwise specified in patients with non-small cell lung cancer receiving immune checkpoint inhibitors
- 10 February 2026
- Published by Elsevier in Respiratory Investigation
- Vol. 64 (2) , 101383
Open AccessFavorable clinical impact of histological subtype with non-small cell carcinoma-not otherwise specified in patients with non-small cell lung cancer receiving immune checkpoint inhibitors
- 4 September 2025
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 783, 152595
Dual-specific phosphatase 5 (DUSP5), upregulated in lung adenocarcinoma, as a potential therapeutic target for lung cancer
- 4 September 2025
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 783, 152595
Dual-specific phosphatase 5 (DUSP5), upregulated in lung adenocarcinoma, as a potential therapeutic target for lung cancer
- 27 April 2024
- Published by Elsevier in Experimental Cell Research
- Vol. 439 (1) , 114057
BRAF promotes anchorage-independent growth but inhibits anchorage-dependent growth in hTERT/Cdk4-Immortalized normal human bronchial epithelial cells
- 27 April 2024
- Published by Elsevier in Experimental Cell Research
- Vol. 439 (1) , 114057
BRAF promotes anchorage-independent growth but inhibits anchorage-dependent growth in hTERT/Cdk4-Immortalized normal human bronchial epithelial cells
- Open Access
- 25 July 2023
- Published by Spandidos Publications in Oncology Letters
- Vol. 26 (3) , 1-15
Silencing of GRHL2 induces epithelial‑to‑mesenchymal transition in lung cancer cell lines with different effects on proliferation and clonogenic growth
Grainyhead‑like 2 (GRHL2) is a transcription factor that suppresses epithelial‑to‑mesenchymal transition (EMT). It has been previously shown that GRHL2 can confer both oncogenic and tumor‑suppressive roles in human cancers, including breast, pancreatic and colorectal cancers. However, its role in lung cancer remains elusive. In the present study, a meta‑analysis of multiple gene expression datasets with clinical data revealed that GRHL2 expression was increased in lung cancer compared with that in the normal tissues. Copy number analysis of GRHL2, performed using datasets of whole exome sequencing involving 151 lung cancer cell lines, revealed frequent amplifications, suggesting that the increased GRHL2 expression may have resulted from gene amplification. A survival meta‑analysis of GRHL2 using The Cancer Genome Atlas (TCGA) dataset showed no association of GRHL2 expression with overall survival. GRHL2 expression was found to be associated with EMT status in lung cancer in TCGA dataset and lung cancer cell lines. GRHL2 knockdown induced partial EMT in the hTERT/Cdk4‑immortalized normal lung epithelial cell line HBEC4KT without affecting proliferation measured by CCK‑8 assays. In addition, GRHL2 silencing caused three lung cancer cell lines, H1975, H2009 and H441, to undergo partial EMT. However, the proliferative effects differed significantly. GRHL2 silencing promoted proliferation but not colony formation in H1975 cells whilst suppressing colony formation without affecting proliferation in H2009 cells, but it did not affect proliferation in H441 cells. These results suggest cell type‑dependent effects of GRHL2 knockdown. Downstream, GRHL2 silencing enhanced the phosphorylation of AKT and ERK, assessed by western blotting with phospho‑specific antibodies, in HBEC4KT, H1975 and H2009 cell lines but not in the H441 cell line. By contrast, transient GRHL2 overexpression did not affect A549 cell proliferation, which lack detectable endogenous expression of the GRHL2 protein. However, GRHL2 overexpression did suppress E‑cadherin expression in A549 cells. These results suggested that GRHL2 does not only function as a tumor suppressor of EMT but can also behave as an oncogene depending on the lung cancer cell‑type context.
- 25 July 2023
- Published by Spandidos Publications in Oncology Letters
- Vol. 26 (3) , 1-15
Open AccessSilencing of GRHL2 induces epithelial‑to‑mesenchymal transition in lung cancer cell lines with different effects on proliferation and clonogenic growth
Grainyhead‑like 2 (GRHL2) is a transcription factor that suppresses epithelial‑to‑mesenchymal transition (EMT). It has been previously shown that GRHL2 can confer both oncogenic and tumor‑suppressive roles in human cancers, including breast, pancreatic and colorectal cancers. However, its role in lung cancer remains elusive. In the present study, a meta‑analysis of multiple gene expression datasets with clinical data revealed that GRHL2 expression was increased in lung cancer compared with that in the normal tissues. Copy number analysis of GRHL2, performed using datasets of whole exome sequencing involving 151 lung cancer cell lines, revealed frequent amplifications, suggesting that the increased GRHL2 expression may have resulted from gene amplification. A survival meta‑analysis of GRHL2 using The Cancer Genome Atlas (TCGA) dataset showed no association of GRHL2 expression with overall survival. GRHL2 expression was found to be associated with EMT status in lung cancer in TCGA dataset and lung cancer cell lines. GRHL2 knockdown induced partial EMT in the hTERT/Cdk4‑immortalized normal lung epithelial cell line HBEC4KT without affecting proliferation measured by CCK‑8 assays. In addition, GRHL2 silencing caused three lung cancer cell lines, H1975, H2009 and H441, to undergo partial EMT. However, the proliferative effects differed significantly. GRHL2 silencing promoted proliferation but not colony formation in H1975 cells whilst suppressing colony formation without affecting proliferation in H2009 cells, but it did not affect proliferation in H441 cells. These results suggest cell type‑dependent effects of GRHL2 knockdown. Downstream, GRHL2 silencing enhanced the phosphorylation of AKT and ERK, assessed by western blotting with phospho‑specific antibodies, in HBEC4KT, H1975 and H2009 cell lines but not in the H441 cell line. By contrast, transient GRHL2 overexpression did not affect A549 cell proliferation, which lack detectable endogenous expression of the GRHL2 protein. However, GRHL2 overexpression did suppress E‑cadherin expression in A549 cells. These results suggested that GRHL2 does not only function as a tumor suppressor of EMT but can also behave as an oncogene depending on the lung cancer cell‑type context.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Methods, Tables 1 - 4, Figures 1 - 7 from Human Lung Epithelial Cells Progressed to Malignancy through Specific Oncogenic Manipulations
PDF file - 2798K, Supplementary Table S1. Primary antibodies used for immunoblotting. Supplementary Table S2. In vitro and in vivo characterization of soft agar clones derived from manipulated HBECs. Supplementary Table S3: Drug response phenotypes of isogenic clones of oncogenically manipulated HBECs. Supplementary Table S4: Significantly differentially expressed genes between tumorigenic (Clones 1, 5 and 11) and non-tumorigenic (Clones 6, 7, 8 and 9) soft agar clones of HBEC3p53,KRAS. Supplementary Figure S1: HBEC anchorage independent and dependent growth, induced senescence, phase contrast and cell cycle analyses of HBECs with and without mutant KRAS and other oncogenic manipulations. Supplementary Figure S2: Histology and immunohistochemical stains of xenograft tumors after oncogenic manipulation of HBECs, and soft agar colony formation after introduction of p53, KRAS, and c-myc oncogenic changes into HBECs. Supplementary Figure S3: Oncogenically manipulated HBECs tested for cell proliferation, stem cell and differentiation marker mRNA expression, and phase contrast morphology after growth in defined and serum containing medium, and TUNEL staining of xenograft HBEC tumors. Supplementary Figure S4: Southern blot analyses of clonal composition of oncogenically manipulated HBECs and tests of soft agar growth of individual clones. Supplementary Figure S5: Representative dose-response curves of HBEC3 and HBEC3p53,KRAS treated with standard lung cancer chemotherapy doublets. Supplementary Figure S6: Cell cycle analysis of soft agar clones of HBEC3p53,KRAS. Supplementary Figure S7: Microarray analysis of 203-probe mRNA gene signature differentially expressed between tumorigenic and non-tumorigenic soft agar clones of HBEC3p53,KRAS against clinical variables. Supplementary Figure S8: Full, uncut blots of immunoblots presented in main article.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods, Tables 1 - 4, Figures 1 - 7 from Human Lung Epithelial Cells Progressed to Malignancy through Specific Oncogenic Manipulations
PDF file - 2798K, Supplementary Table S1. Primary antibodies used for immunoblotting. Supplementary Table S2. In vitro and in vivo characterization of soft agar clones derived from manipulated HBECs. Supplementary Table S3: Drug response phenotypes of isogenic clones of oncogenically manipulated HBECs. Supplementary Table S4: Significantly differentially expressed genes between tumorigenic (Clones 1, 5 and 11) and non-tumorigenic (Clones 6, 7, 8 and 9) soft agar clones of HBEC3p53,KRAS. Supplementary Figure S1: HBEC anchorage independent and dependent growth, induced senescence, phase contrast and cell cycle analyses of HBECs with and without mutant KRAS and other oncogenic manipulations. Supplementary Figure S2: Histology and immunohistochemical stains of xenograft tumors after oncogenic manipulation of HBECs, and soft agar colony formation after introduction of p53, KRAS, and c-myc oncogenic changes into HBECs. Supplementary Figure S3: Oncogenically manipulated HBECs tested for cell proliferation, stem cell and differentiation marker mRNA expression, and phase contrast morphology after growth in defined and serum containing medium, and TUNEL staining of xenograft HBEC tumors. Supplementary Figure S4: Southern blot analyses of clonal composition of oncogenically manipulated HBECs and tests of soft agar growth of individual clones. Supplementary Figure S5: Representative dose-response curves of HBEC3 and HBEC3p53,KRAS treated with standard lung cancer chemotherapy doublets. Supplementary Figure S6: Cell cycle analysis of soft agar clones of HBEC3p53,KRAS. Supplementary Figure S7: Microarray analysis of 203-probe mRNA gene signature differentially expressed between tumorigenic and non-tumorigenic soft agar clones of HBEC3p53,KRAS against clinical variables. Supplementary Figure S8: Full, uncut blots of immunoblots presented in main article.
- Open Access
- 7 February 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (2) , 561
Recent Advances in Localized Immunomodulation Technology: Application of NIR-PIT toward Clinical Control of the Local Immune System
Current immunotherapies aim to modulate the balance among different immune cell populations, thereby controlling immune reactions. However, they often cause immune overactivation or over-suppression, which makes them difficult to control. Thus, it would be ideal to manipulate immune cells at a local site without disturbing homeostasis elsewhere in the body. Recent technological developments have enabled the selective targeting of cells and tissues in the body. Photo-targeted specific cell therapy has recently emerged among these. Near-infrared photoimmunotherapy (NIR-PIT) has surfaced as a new modality for cancer treatment, which combines antibodies and a photoabsorber, IR700DX. NIR-PIT is in testing as an international phase III clinical trial for locoregional recurrent head and neck squamous cell carcinoma (HNSCC) patients (LUZERA-301, NCT03769506), with a fast-track designation by the United States Food and Drug Administration (US-FDA). In Japan, NIR-PIT for patients with recurrent head and neck cancer was conditionally approved in 2020. Although NIR-PIT is commonly used for cancer therapy, it could also be exploited to locally eliminate certain immune cells with antibodies for a specific immune cell marker. This strategy can be utilized for anti-allergic therapy. Herein, we discuss the recent technological advances in local immunomodulation technology. We introduce immunomodulation technology with NIR-PIT and demonstrate an example of the knockdown of regulatory T cells (Tregs) to enhance local anti-tumor immune reactions.
- 7 February 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (2) , 561
Open AccessRecent Advances in Localized Immunomodulation Technology: Application of NIR-PIT toward Clinical Control of the Local Immune System
Current immunotherapies aim to modulate the balance among different immune cell populations, thereby controlling immune reactions. However, they often cause immune overactivation or over-suppression, which makes them difficult to control. Thus, it would be ideal to manipulate immune cells at a local site without disturbing homeostasis elsewhere in the body. Recent technological developments have enabled the selective targeting of cells and tissues in the body. Photo-targeted specific cell therapy has recently emerged among these. Near-infrared photoimmunotherapy (NIR-PIT) has surfaced as a new modality for cancer treatment, which combines antibodies and a photoabsorber, IR700DX. NIR-PIT is in testing as an international phase III clinical trial for locoregional recurrent head and neck squamous cell carcinoma (HNSCC) patients (LUZERA-301, NCT03769506), with a fast-track designation by the United States Food and Drug Administration (US-FDA). In Japan, NIR-PIT for patients with recurrent head and neck cancer was conditionally approved in 2020. Although NIR-PIT is commonly used for cancer therapy, it could also be exploited to locally eliminate certain immune cells with antibodies for a specific immune cell marker. This strategy can be utilized for anti-allergic therapy. Herein, we discuss the recent technological advances in local immunomodulation technology. We introduce immunomodulation technology with NIR-PIT and demonstrate an example of the knockdown of regulatory T cells (Tregs) to enhance local anti-tumor immune reactions.
- Open Access
- 11 July 2022
- Published by MDPI AG in Biomedicines
- Vol. 10 (7) , 1662
Near-Infrared Photoimmunotherapy for Thoracic Cancers: A Translational Perspective
The conventional treatment of thoracic tumors includes surgery, anticancer drugs, radiation, and cancer immunotherapy. Light therapy for thoracic tumors has long been used as an alternative; conventional light therapy also called photodynamic therapy (PDT) has been used mainly for early-stage lung cancer. Recently, near-infrared photoimmunotherapy (NIR-PIT), which is a completely different concept from conventional PDT, has been developed and approved in Japan for the treatment of recurrent and previously treated head and neck cancer because of its specificity and effectiveness. NIR-PIT can apply to any target by changing to different antigens. In recent years, it has become clear that various specific and promising targets are highly expressed in thoracic tumors. In combination with these various specific targets, NIR-PIT is expected to be an ideal therapeutic approach for thoracic tumors. Additionally, techniques are being developed to further develop NIR-PIT for clinical practice. In this review, NIR-PIT is introduced, and its potential therapeutic applications for thoracic cancers are described.
- 11 July 2022
- Published by MDPI AG in Biomedicines
- Vol. 10 (7) , 1662
Open AccessNear-Infrared Photoimmunotherapy for Thoracic Cancers: A Translational Perspective
The conventional treatment of thoracic tumors includes surgery, anticancer drugs, radiation, and cancer immunotherapy. Light therapy for thoracic tumors has long been used as an alternative; conventional light therapy also called photodynamic therapy (PDT) has been used mainly for early-stage lung cancer. Recently, near-infrared photoimmunotherapy (NIR-PIT), which is a completely different concept from conventional PDT, has been developed and approved in Japan for the treatment of recurrent and previously treated head and neck cancer because of its specificity and effectiveness. NIR-PIT can apply to any target by changing to different antigens. In recent years, it has become clear that various specific and promising targets are highly expressed in thoracic tumors. In combination with these various specific targets, NIR-PIT is expected to be an ideal therapeutic approach for thoracic tumors. Additionally, techniques are being developed to further develop NIR-PIT for clinical practice. In this review, NIR-PIT is introduced, and its potential therapeutic applications for thoracic cancers are described.
- 8 February 2022
- Published by Elsevier in Experimental Cell Research
- Vol. 414 (1) , 113053
Resistance to mutant KRAS-induced senescence in an hTERT/Cdk4-immortalized normal human bronchial epithelial cell line
- 8 February 2022
- Published by Elsevier in Experimental Cell Research
- Vol. 414 (1) , 113053
Resistance to mutant KRAS-induced senescence in an hTERT/Cdk4-immortalized normal human bronchial epithelial cell line